• NeOnc Technologies secured Department of Health – Abu Dhabi IND authorization for NEO212, opening an additional clinical development pathway for glioblastoma.
• The oral perillyl alcohol–temozolomide conjugate has completed Phase 1 dose escalation; 610 mg was selected as the recommended Phase 2 dose.
• The company plans a Type B end-of-Phase 1 meeting with the FDA to discuss next steps and potential registrational pathways.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202606220845NEWSFILECNPR____20260622_302323_1) on June 22, 2026, and is solely responsible for the information contained therein.